Sanofi has announced a definitive agreement to acquire Dynavax Technologies Corporation in an all-cash transaction valuing the vaccine company at approximately USD 2.2 billion. The deal, priced at USD 15.50 per share, aims to bolster Sanofi's position in the adult immunisation market. Dynavax's portfolio includes the commercially available Heplisav-B® hepatitis B (HBV) vaccine for adults and a differentiated shingles vaccine candidate, Z-1018, currently in Phase I/II development.

Heplisav-B is distinguished by a two-dose regimen administered over one month, offering faster seroprotection compared to traditional three-dose schedules administered over six months. Sanofi's acquisition addresses a significant unmet need, particularly in places like the US where an estimated 100 million adults born before 1991 remain unvaccinated against HBV. Dynavax also highlights the substantial burden of shingles, which affects about one in three adults during their lifetime, often causing severe pain and complications.

PharmCube's NextBiopharm® database shows that Dynavax is the fourth company acquired by Sanofi this year. Click here to request a free trial for NextBiopharm®.